Finzati - Logo
BIIB logo

Biogen Inc.

BIIB • Drug Manufacturers - General
$220.83
▼ -3.68 (-1.64%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.
Market Cap
$33.17B
Growth
20.9%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 13.2%Positive free cash flow · 13.98Consistent free cash flow · 5/5Reasonable earnings multiple · 19.96Manageable debt level · 0.38
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$220.83
Change-1.64%
Shares Out148.70M
Market Cap$33.17B
Enterprise Value$39.97B
52W Range124.56 - 219.72
Beta0.16
P/E39.72
P/S3.33
P/B1.76
P/FCF11.19
EV/Sales4.02

Investment DNA

How strong this company looks for long-term investors

70
out of 100
Business Quality
Margins, moat, returns
67/100
Financial Strength
Debt, cash, stability
89/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
82/100
Why this score▼
Stable or improving margins · 13.2%Positive free cash flow · 13.98Consistent free cash flow · 5/5Reasonable earnings multiple · 19.96Manageable debt level · 0.38Healthy liquidity · 2.68

Analyst view

Analyst sentiment and price target

BIIB
Analyst sentiment
Based on 49 analyst votes · 2026-09-03
81/100
Bullish
Bullish
31
Hold
17
Bearish
1
Price Target
2026-07-31
Low
$157.00
Mean
$228.32
Median
$231.00
High
$300.00

Company Overview

IPO: 9/17/1991
Industry: Drug Manufacturers - General
P/B i: 1.76
Debt / Equity i: 0.38
Operating Margin: 19.14%
Net Margin: 13.18%
ROE i: -
ROIC: -

Financial Health

Score18 / 20
Debt / Equity: 0.38
Current Ratio: 2.68
Quick Ratio: 2.03
Status: Strong

Insider Transactions

Recent executive and insider activity

Freire Maria C
Transaction: 06/09/2026
BUY
Change
+2,005
Price
Not reported
Filing
06/11/2026
Type
BUY
Minor Lloyd
Transaction: 06/09/2026
BUY
Change
+1,505
Price
Not reported
Filing
06/11/2026
Type
BUY
Pangalos Menelas N
Transaction: 06/09/2026
SELL
Change
-2,370
Price
Not reported
Filing
06/11/2026
Type
SELL